Repare Therapeutics
Repare Therapeutics
RPTX
NASDAQ
2.91
USD
110.87%
About
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair.
The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations.
Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 91.2K |
| Three Month Average Volume | 2.9M |
| High Low | |
| Fifty-Two Week High | 13.85 USD |
| Fifty-Two Week Low | 2.78 USD |
| Fifty-Two Week High Date | 20 Sep 2023 |
| Fifty-Two Week Low Date | 09 Aug 2024 |
| Price and Volume | |
| Current Price | 2.91 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -16.28% |
| Thirteen Week Relative Price Change | -21.87% |
| Twenty-Six Week Relative Price Change | -63.24% |
| Fifty-Two Week Relative Price Change | -76.21% |
| Year-to-Date Relative Price Change | -66.34% |
| Price Change | |
| One Day Price Change | -3.32% |
| Thirteen Week Price Change | -16.38% |
| Twenty-Six Week Price Change | -59.58% |
| Five Day Price Change | -3.32% |
| Fifty-Two Week Price Change | -70.18% |
| Year-to-Date Price Change | -60.14% |
| Month-to-Date Price Change | -22.19% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 5.02849 USD |
| Book Value Per Share (Most Recent Quarter) | 4.79855 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 5.02849 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.79855 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.19774 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.21475 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.60933 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.22829 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.63386 USD |
| Normalized (Last Fiscal Year) | -2.22829 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.22829 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.62119 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.22829 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.63386 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.30223 USD |
| Cash Per Share (Most Recent Quarter) | 4.9033 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.18194 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.55884 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.87464 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -128 |
| Cash Flow Revenue (Trailing Twelve Months) | -116 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -121.83% |
| Pretax Margin (Last Fiscal Year) | -201.79% |
| Pretax Margin (5 Year) | -161.21% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -227.30% |
| Operating Margin (Trailing Twelve Months) | -139.46% |
| Operating Margin (5 Year) | -170.61% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -183.44% |
| Net Profit Margin (Trailing Twelve Months) | -99.76% |
| Net Profit Margin (5 Year) | -162.76% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 79.35% |
| Tangible Book Value (5 Year) | 86.15% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -96.45% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -58.79% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 623.53% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 27.16% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -188.65% |
| EPS Change (Trailing Twelve Months) | -915.39% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -208,123,000 |
| Net Debt (Last Fiscal Year) | -223,627,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 2 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -129,096,000 |
| Free Cash Flow (Trailing Twelve Months) | -80,006,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -30.36% |
| Return on Assets (Trailing Twelve Months) | -25.52% |
| Return on Assets (5 Year) | -23.40% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -38.16% |
| Return on Equity (Trailing Twelve Months) | -30.52% |
| Return on Equity (5 Year) | -34.35% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -37.50% |
| Return on Investment (Trailing Twelve Months) | -30.30% |
| Return on Investment (5 Year) | -26.37% |